Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Healthcare Biotechnology
Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Theratechnologies Inc > Genfit
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(258)
•••
Comment by qwerty22on May 03, 2021 10:50am
78 Views
Post# 33113874

RE:RE:RE:RE:RE:Genfit

RE:RE:RE:RE:RE:Genfit

So some expectation leading companies like mdgl might have a drug on the market by 2023. So yes maybe diagnostics by that time for the clinic. But no move as yet in clinical trials.


Wino115 wrote: The importance of this test is that it may become the gateway of proof needed for insurance or national health systems to allow you to move to treatment.  It's always been a very "fuzzy" disease to diagnose and document for treatment.  This may allow that and legitimize the market size that has a wide confidence interval around it now. Anything to legitimize and identify the disease is good news. I don't think it's that expensive either.
 

scarlet1967 wrote: I believe noninvasive diagnostics will be replacing biopsies soon maybe/possibly soon enough for THTX’s trial as it has been the advisory opinion of KOLs worldwide for quite a while now Apart from blood tests to identify biomarkers associated with NASH there are other diagnostic tools like measurement of liver stiffness/enzymes and ultrasound to value live fat when combined together they have proven to be as accurate as biopsies less invasive/expensive.
palinc2000 wrote:

Will biopsies still need to be performed for our Nash Trial?

 


 

 


 




<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities